8-K Announcements
6Material company update
May 4, 2026·SEC
Material company update
Apr 29, 2026·SEC
Material company update
Mar 31, 2026·SEC
Vertex Pharmaceuticals Incorporated(VRTX)Earnings, Financials & Key Ratios
VRTX•NASDAQ
29.5× P/E·Price updated Jun 19, 2026
AboutVertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.Show more
- Revenue$12.07B+9.6%
- EBITDA$4.97B+18431.7%
- Net Income$3.95B+838.1%
- EPS (Diluted)15.32+836.5%
- Gross Margin85.03%-1.3%
- EBITDA Margin41.14%+16831.8%
- Operating Margin39.43%+1965.6%
- Net Margin32.74%+773.6%
- ROE22.54%+815.3%
VRTX Key Insights
Vertex Pharmaceuticals Incorporated (VRTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓FCF machine: 26.5% free cash flow margin
- ✓Strong 5Y sales CAGR of 14.2%
- ✓Healthy 5Y average net margin of 26.5%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when VRTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
VRTX Price & Volume
Vertex Pharmaceuticals Incorporated (VRTX) stock price & volume — 10-year historical chart
Loading chart...
VRTX Growth Metrics
Vertex Pharmaceuticals Incorporated (VRTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years27.88%
5 Years14.24%
3 Years10.58%
TTM10.41%
Profit CAGR
10 Years-
5 Years7.83%
3 Years5.97%
TTM538.7%
EPS CAGR
10 Years-
5 Years8.29%
3 Years6.12%
TTM530.1%
Return on Capital
10 Years17.8%
5 Years20.51%
3 Years14.67%
Last Year23.08%
VRTX Recent Earnings
Vertex Pharmaceuticals Incorporated (VRTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 4, 2026Metric
Actual
Est
EPS
$4.47+5.4%
$4.24
Rev
$3.0B-0.2%
$3.0B
Q1 2026
Feb 12, 2026Metric
Actual
Est
EPS
$5.03-1.6%
$5.11
Rev
$3.2B+0.2%
$3.2B
Q4 2025
Nov 3, 2025Metric
Actual
Est
EPS
$4.80+5.0%
$4.57
Rev
$3.1B+0.6%
$3.1B
Q3 2025
Aug 4, 2025Metric
Actual
Est
EPS
$4.52+5.4%
$4.29
Rev
$3.0B+2.0%
$2.9B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 4, 2026 | $4.47vs $4.24+5.4% | $3.0Bvs $3.0B-0.2% |
| Q1 2026 | Feb 12, 2026 | $5.03vs $5.11-1.6% | $3.2Bvs $3.2B+0.2% |
| Q4 2025 | Nov 3, 2025 | $4.80vs $4.57+5.0% | $3.1Bvs $3.1B+0.6% |
| Q3 2025 | Aug 4, 2025 | $4.52vs $4.29+5.4% | $3.0Bvs $2.9B+2.0% |
Based on last 12 quarters of dataView full earnings history →
VRTX Peer Comparison
Vertex Pharmaceuticals Incorporated (VRTX) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 REGN | 63.37B | 609.94 | 14.70 | 0.99% | 29.65% | 14.32% | 0.09 | |
 ALNY | 37.1B | 278.09 | 119.35 | 65.19% | 13.46% | 98.29% | 1.62 | |
 BMRN | 10.52B | 54.69 | 30.38 | 12.87% | 8.29% | 4.41% | 0.11 | |
 SRPT | 1.85B | 17.53 | -2.46 | 15.58% | 2.98% | 4.89% | 0.91 | |
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% | ||
 IONS | 12.25B | 74.12 | -31.14 | 33.87% | -30.87% | -58.57% | 5.35 | |
 ABBV | 383.17B | 216.63 | 91.41 | 8.57% | 6.91% | 62.15% | ||
 BIIB | 29.02B | 196.58 | 22.26 | 1.39% | 13.92% | 7.55% | 0.38 |
Compare VRTX vs Peers
Vertex Pharmaceuticals Incorporated (VRTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
VRTX Income Statement
Vertex Pharmaceuticals Incorporated (VRTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 2.49B | 3.05B | 4.16B | 6.21B | 7.57B | 8.93B | 9.87B | 11.02B | 12.07B | 12.26B |
Revenue Growth % | 46.2% | 22.46% | 36.59% | 49.07% | 22.06% | 17.91% | 10.51% | 11.66% | 9.57% | 10.41% |
Cost of Goods Sold | 275.12M | 409.54M | 547.76M | 736.3M | 904.2M | 1.08B | 1.26B | 1.53B | 1.81B | 1.68B |
COGS % of Revenue | 11.05% | 13.44% | 13.16% | 11.86% | 11.94% | 12.1% | 12.79% | 13.89% | 14.97% | - |
Gross Profit | 2.21B▲ 0% | 2.64B▲ 19.2% | 3.62B▲ 37.0% | 5.47B▲ 51.3% | 6.67B▲ 22.0% | 7.85B▲ 17.7% | 8.61B▲ 9.6% | 9.49B▲ 10.3% | 10.27B▲ 8.2% | 10.57B▲ 0% |
Gross Margin % | 88.95% | 86.56% | 86.84% | 88.14% | 88.06% | 87.9% | 87.21% | 86.11% | 85.03% | 86.28% |
Gross Profit Growth % | 48.39% | 19.18% | 37.04% | 51.29% | 21.96% | 17.69% | 9.64% | 10.25% | 8.2% | - |
Operating Expenses | 1.82B | 1.97B | 2.41B | 2.61B | 3.89B | 3.54B | 4.78B | 9.72B | 5.51B | 5.8B |
OpEx % of Revenue | 73.16% | 64.78% | 57.97% | 42.11% | 51.37% | 39.67% | 48.38% | 88.23% | 45.61% | - |
Selling, General & Admin | 496.08M | 557.62M | 658.5M | 770.5M | 840.1M | 944.7M | 1.14B | 1.46B | 1.75B | 1.85B |
SG&A % of Revenue | 19.93% | 18.3% | 15.82% | 12.42% | 11.09% | 10.58% | 11.52% | 13.29% | 14.52% | - |
Research & Development | 1.32B | 1.42B | 1.75B | 1.83B | 3.05B | 2.66B | 3.16B | 3.63B | 3.75B | 3.95B |
R&D % of Revenue | 53.23% | 46.48% | 42.15% | 29.48% | 40.28% | 29.74% | 32.05% | 32.94% | 31.09% | - |
Other Operating Expenses | 0 | -790K | 0 | 13.06M | 0 | -57.5M | 475.5M | 4.63B | 0 | 700K |
Operating Income | 123.24M▲ 0% | 635.15M▲ 415.4% | 1.2B▲ 88.5% | 2.86B▲ 138.5% | 2.78B▼ 2.6% | 4.31B▲ 54.8% | 3.83B▼ 11.0% | -232.9M▼ 106.1% | 4.76B▲ 2144.1% | 4.78B▲ 0% |
Operating Margin % | 4.95% | 20.84% | 28.77% | 46.03% | 36.73% | 48.23% | 38.83% | -2.11% | 39.43% | 38.97% |
Operating Income Growth % | 1140.37% | 415.36% | 88.55% | 138.51% | -2.6% | 54.83% | -11.04% | -106.08% | 2144.1% | - |
EBITDA | 184.64M | 707.57M | 1.3B | 2.97B | 2.91B | 4.46B | 4.01B | -27.1M | 4.97B | 4.93B |
EBITDA Margin % | 7.42% | 23.22% | 31.34% | 47.79% | 38.39% | 49.89% | 40.66% | -0.25% | 41.14% | 40.27% |
EBITDA Growth % | 158.84% | 283.22% | 84.36% | 127.35% | -1.96% | 53.24% | -9.93% | -100.68% | 18431.73% | 1013.48% |
D&A (Non-Cash Add-back) | 61.4M | 72.42M | 106.94M | 109.52M | 125.6M | 148.3M | 181.3M | 205.8M | 207.2M | 158.8M |
EBIT | 53.61M | 672.71M | 1.45B | 3.17B | 2.79B | 4.29B | 4.42B | 279.1M | 4.76B | 5.03B |
Net Interest Income | -57.55M | -34.12M | 5.2M | -36M | -56.6M | 89.8M | 570.6M | 567.5M | 477.6M | 474.5M |
Interest Income | 11.75M | 0 | 63.68M | 22.2M | 4.9M | 144.6M | 614.7M | 598.1M | 490.9M | 484.8M |
Interest Expense | 69.3M | 34.12M | 58.5M | 58.15M | 61.5M | 54.8M | 44.1M | 30.6M | 13.3M | 10.3M |
Other Income/Expense | -138.93M | -34.91M | 197.42M | 260.6M | -51.7M | -75M | 547.8M | 481.4M | -117.5M | 389.9M |
Pretax Income | -15.69M▲ 0% | 600.24M▲ 3925.9% | 1.39B▲ 132.4% | 3.12B▲ 123.4% | 2.73B▼ 12.4% | 4.23B▲ 55.0% | 4.38B▲ 3.5% | 248.5M▼ 94.3% | 4.64B▲ 1768.5% | 5.17B▲ 0% |
Pretax Margin % | -0.63% | 19.7% | 33.51% | 50.23% | 36.05% | 47.39% | 44.38% | 2.25% | 38.45% | 42.15% |
Income Tax | -107.32M | -1.49B | 218.11M | 405.15M | 388.3M | 910.4M | 760.2M | 784.1M | 690M | 827.4M |
Effective Tax Rate % | 684.07% | -247.71% | 15.64% | 13% | 14.22% | 21.51% | 17.36% | 315.53% | 14.86% | 16.02% |
Net Income | 263.48M▲ 0% | 2.1B▲ 695.8% | 1.18B▼ 43.9% | 2.71B▲ 130.4% | 2.34B▼ 13.6% | 3.32B▲ 41.8% | 3.62B▲ 9.0% | -535.6M▼ 114.8% | 3.95B▲ 838.1% | 4.34B▲ 0% |
Net Margin % | 10.59% | 68.8% | 28.27% | 43.7% | 30.92% | 37.2% | 36.68% | -4.86% | 32.74% | 35.4% |
Net Income Growth % | 335.14% | 695.83% | -43.88% | 130.43% | -13.63% | 41.84% | 8.96% | -114.8% | 838.09% | 538.7% |
Net Income (Continuing) | 91.64M | 2.09B | 1.18B | 2.71B | 2.34B | 3.32B | 3.62B | -535.6M | 3.95B | 4.34B |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 13.73M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 1.04▲ 0% | 8.09▲ 677.9% | 4.51▼ 44.3% | 10.29▲ 128.2% | 9.01▼ 12.4% | 12.82▲ 42.3% | 13.89▲ 8.3% | -2.08▼ 115.0% | 15.32▲ 836.5% | 16.93▲ 0% |
EPS Growth % | 326.09% | 677.88% | -44.25% | 128.16% | -12.44% | 42.29% | 8.35% | -114.97% | 836.54% | 530.1% |
EPS (Basic) | 1.06 | 8.25 | 4.58 | 10.44 | 9.09 | 12.97 | 14.05 | -2.08 | 15.46 | - |
Diluted Shares Outstanding | 253.22M | 259.19M | 260.67M | 263.4M | 259.9M | 259.1M | 260.5M | 257.9M | 258M | 256.3M |
Basic Shares Outstanding | 248.86M | 254.29M | 256.73M | 259.84M | 257.7M | 256.1M | 257.7M | 257.5M | 255.7M | 254.1M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
VRTX Balance Sheet
Vertex Pharmaceuticals Incorporated (VRTX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 2.65B | 3.84B | 4.82B | 8.13B | 9.56B | 13.23B | 14.14B | 9.6B | 11.2B | 11.73B |
Cash & Short-Term Investments | 2.09B | 3.17B | 3.81B | 6.66B | 7.52B | 10.78B | 11.22B | 6.12B | 6.61B | 7.25B |
Cash Only | 1.67B | 2.65B | 3.11B | 5.99B | 6.79B | 10.5B | 10.37B | 4.57B | 5.09B | 5.49B |
Short-Term Investments | 423.25M | 518.11M | 698.97M | 670.7M | 729.9M | 274.5M | 849.2M | 1.55B | 1.52B | 1.75B |
Accounts Receivable | 385.99M | 409.69M | 633.52M | 885.4M | 1.14B | 1.44B | 1.56B | 1.61B | 2.05B | 2B |
Days Sales Outstanding | 56.61 | 49.07 | 55.55 | 52.08 | 54.78 | 58.94 | 57.82 | 53.31 | 62.05 | 58.74 |
Inventory | 111.83M | 124.36M | 167.5M | 280.78M | 353.1M | 460.6M | 738.8M | 1.21B | 1.69B | 1.77B |
Days Inventory Outstanding | 148.36 | 110.84 | 111.62 | 139.19 | 142.54 | 155.62 | 213.64 | 287.47 | 340.7 | 357.14 |
Other Current Assets | 0 | 0 | 0 | 79.72M | 103.7M | 121.9M | 86.1M | 206.5M | 748.6M | 720.8M |
Total Non-Current Assets | 897.05M | 2.4B | 3.5B | 3.62B | 3.87B | 4.92B | 8.59B | 12.94B | 14.94B | 14.75B |
Property, Plant & Equipment | 789.44M | 812M | 833.28M | 1.28B | 1.42B | 1.46B | 1.45B | 2.58B | 3.08B | 1.61B |
Fixed Asset Turnover | 3.15x | 3.75x | 5.00x | 4.83x | 5.32x | 6.13x | 6.79x | 4.26x | 3.92x | 4.73x |
Goodwill | 50.38M | 50.38M | 1B | 1B | 1B | 1.09B | 1.09B | 1.09B | 1.09B | 1.09B |
Intangible Assets | 29M | 0 | 400M | 400M | 400M | 603.6M | 839.9M | 825.9M | 424.2M | 418.5M |
Long-Term Investments | 20.45M | 0 | 0 | 0 | 0 | 112.2M | 2.5B | 5.11B | 5.81B | 22.93B |
Other Non-Current Assets | 6.95M | 40.73M | 69.38M | 49.3M | 110.8M | 409.6M | 895.3M | 999.3M | 1.14B | 2.94B |
Total Assets | 3.55B▲ 0% | 6.25B▲ 76.1% | 8.32B▲ 33.2% | 11.75B▲ 41.3% | 13.43B▲ 14.3% | 18.15B▲ 35.1% | 22.73B▲ 25.2% | 22.53B▼ 0.9% | 26.14B▲ 16.0% | 26.48B▲ 0% |
Asset Turnover | 0.70x | 0.49x | 0.50x | 0.53x | 0.56x | 0.49x | 0.43x | 0.49x | 0.46x | 0.48x |
Asset Growth % | 22.54% | 76.14% | 33.18% | 41.27% | 14.3% | 35.13% | 25.23% | -0.87% | 16.02% | 62.95% |
Total Current Liabilities | 807.26M | 1.12B | 1.33B | 1.88B | 2.14B | 2.74B | 3.55B | 3.56B | 3.86B | 3.88B |
Accounts Payable | 73.99M | 110.99M | 87.61M | 155.1M | 195M | 303.9M | 364.9M | 413M | 461.7M | 489.3M |
Days Payables Outstanding | 98.17 | 98.92 | 58.38 | 76.89 | 78.72 | 102.68 | 105.52 | 98.49 | 93.25 | 294.58 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 92.3M | 82.8M | 0 |
Deferred Revenue (Current) | 237.57M | 24.87M | 62.33M | 191.5M | 171.7M | 159.6M | 170.3M | 206.8M | 171.8M | 171.8M |
Other Current Liabilities | -203.2M | 20.27M | 29.18M | 83.5M | 16.5M | 62.5M | 50.7M | 2.5B | 2.75B | 407.1M |
Current Ratio | 3.28x | 3.43x | 3.61x | 4.33x | 4.46x | 4.83x | 3.99x | 2.69x | 2.90x | 3.02x |
Quick Ratio | 3.14x | 3.32x | 3.49x | 4.18x | 4.30x | 4.66x | 3.78x | 2.35x | 2.46x | 2.57x |
Cash Conversion Cycle | 106.81 | 60.99 | 108.78 | 114.38 | 118.6 | 111.89 | 165.94 | 242.28 | 309.5 | 121.3 |
Total Non-Current Liabilities | 696.45M | 690.4M | 898.39M | 1.19B | 1.19B | 1.5B | 1.6B | 2.56B | 3.62B | 3.24B |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.85B | 0 |
Capital Lease Obligations | 583.9M | 581.55M | 622.87M | 889.5M | 887.2M | 810.3M | 724.7M | 1.66B | 1.95B | 7.3B |
Deferred Tax Liabilities | 6.34M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.31B | 1.31B |
Other Non-Current Liabilities | 27.77M | 26.28M | 186.76M | 298M | 303.3M | 685.8M | 877.7M | 901.8M | -1.49B | 1.26B |
Total Liabilities | 1.5B | 1.81B | 2.23B | 3.06B | 3.33B | 4.24B | 5.15B | 6.12B | 7.48B | 7.12B |
Total Debt | 606.43M | 586.82M | 661.66M | 931.9M | 967.4M | 899.7M | 808.4M | 1.75B | 3.88B | 1.99B |
Net Debt | -1.06B | -2.06B | -2.45B | -5.06B | -5.83B | -9.6B | -9.56B | -2.82B | -1.21B | -3.51B |
Debt / Equity | 0.30x | 0.13x | 0.11x | 0.11x | 0.10x | 0.06x | 0.05x | 0.11x | 0.21x | 0.10x |
Debt / EBITDA | 3.28x | 0.83x | 0.51x | 0.31x | 0.33x | 0.20x | 0.20x | - | 0.78x | 0.40x |
Net Debt / EBITDA | -5.74x | -2.92x | -1.88x | -1.70x | -2.00x | -2.16x | -2.38x | - | -0.24x | -0.71x |
Interest Coverage | 0.77x | 19.72x | 24.84x | 54.60x | 45.40x | 78.23x | 100.32x | 9.12x | 357.95x | 488.09x |
Total Equity | 2.04B▲ 0% | 4.44B▲ 117.2% | 6.09B▲ 37.2% | 8.69B▲ 42.8% | 10.1B▲ 16.3% | 13.91B▲ 37.7% | 17.58B▲ 26.4% | 16.41B▼ 6.7% | 18.67B▲ 13.7% | 19.36B▲ 0% |
Equity Growth % | 52.62% | 117.17% | 37.2% | 42.75% | 16.27% | 37.75% | 26.36% | -6.66% | 13.75% | 58.17% |
Book Value per Share | 8.07 | 17.11 | 23.34 | 32.98 | 38.86 | 53.70 | 67.49 | 63.63 | 72.35 | 75.54 |
Total Shareholders' Equity | 2.03B | 4.44B | 6.09B | 8.69B | 10.1B | 13.91B | 17.58B | 16.41B | 18.67B | 19.36B |
Common Stock | 2.51M | 2.55M | 2.59M | 2.6M | 2.5M | 2.6M | 2.6M | 2.6M | 2.5M | 2.5M |
Retained Earnings | -5.12B | -2.99B | -1.85B | 858.67M | 3.2B | 6.52B | 10.14B | 9.61B | 13.56B | 14.59B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -11.57M | 659K | -1.97M | -68.48M | 15.9M | 800K | -14.3M | 127.8M | -15.9M | 24.8M |
Minority Interest | 13.73M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VRTX Cash Flow Statement
Vertex Pharmaceuticals Incorporated (VRTX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 844.94M | 1.27B | 1.57B | 3.25B | 2.64B | 4.13B | 3.54B | -492.6M | 3.63B | 4.24B |
Operating CF Margin % | 33.95% | 41.68% | 37.7% | 52.43% | 34.9% | 46.24% | 35.84% | -4.47% | 30.07% | - |
Operating CF Growth % | 257.87% | 50.34% | 23.54% | 107.32% | -18.75% | 56.23% | -14.35% | -113.93% | 837.19% | 178.79% |
Net Income | 91.64M | 2.09B | 1.18B | 2.71B | 2.34B | 3.32B | 3.62B | -535.6M | 3.95B | 4.34B |
Depreciation & Amortization | 61.4M | 72.42M | 106.94M | 109.52M | 125.6M | 148.3M | 181.3M | 207.2M | 207.2M | 217.3M |
Stock-Based Compensation | 290.74M | 325.05M | 360.49M | 429.5M | 441.4M | 491.3M | 581.2M | 698.5M | 0 | 686.2M |
Deferred Taxes | -120.51M | -1.51B | 167.39M | 277.34M | -154.6M | -275.9M | -536.5M | -348.8M | -510.8M | -384.5M |
Other Non-Cash Items | 506.42M | 60.02M | -176.2M | -220.04M | -5.8M | 103.4M | -42.6M | 900K | 1.18B | 69.2M |
Working Capital Changes | 15.26M | 238.02M | -66.1M | -54.45M | -105.2M | 340.8M | -265.7M | -514.8M | -1.2B | -685.9M |
Change in Receivables | -71.76M | -108.15M | -225.59M | -223.44M | -274.7M | -358.6M | -84.1M | -99.3M | -347.3M | -137.9M |
Change in Inventory | -44.98M | -31.96M | -64.05M | -132.01M | -92.8M | -136.4M | -322.9M | -517.3M | -524.2M | -454.8M |
Change in Payables | 8.75M | 36.55M | -22.79M | 51.28M | 31.9M | 120.8M | 48.7M | 49.5M | 36.8M | 46.2M |
Cash from Investing | -437.68M | -202.16M | -1.24B | 99.39M | -340.9M | -321.1M | -3.14B | -3.77B | -945.4M | -1.32B |
Capital Expenditures | -259.42M | -95.52M | -75.45M | -259.8M | -235M | -204.7M | -200.4M | -297.7M | -437.6M | -530.3M |
CapEx % of Revenue | 10.42% | 3.13% | 1.81% | 4.19% | 3.1% | 2.29% | 2.03% | 2.7% | 3.62% | 4.33% |
Acquisitions | -160M | 0 | -1.15B | -418.24M | 77M | -295.9M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 145.11M | -22.82M | 0 | 418.24M | -77M | -47.8M | -89M | -241.7M | -24.7M | -19.4M |
Cash from Financing | 68.4M | -71.22M | 126.77M | -505.28M | -1.48B | -67.7M | -562.2M | -1.49B | -2.26B | -2.12B |
Debt Issued (Net) | -284.67M | -12.55M | -29.14M | -29.02M | -18.7M | -85.5M | -44.9M | -33.6M | -5.4M | -4.1M |
Equity Issued (Net) | 344.84M | -60.75M | 151.23M | -274.19M | -1.32B | 186.3M | -293M | -1.06B | -1.89B | -1.79B |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | -350.04M | -192.01M | -539.14M | -1.43B | 0 | -427.6M | -1.18B | -2.02B | -1.93B |
Other Financing | 8.23M | 2.08M | 4.68M | -202.07M | -130.2M | -168.5M | -224.3M | -398.8M | -366.2M | -322.9M |
Net Change in Cash | 481.47M▲ 0% | 990.73M▲ 105.8% | 462.43M▼ 53.3% | 2.87B▲ 520.2% | 811.2M▼ 71.7% | 3.71B▲ 357.6% | -139.7M▼ 103.8% | -5.8B▼ 4051.8% | 515.6M▲ 108.9% | 819.5M▲ 0% |
Free Cash Flow | 585.52M▲ 0% | 1.17B▲ 100.6% | 1.49B▲ 27.2% | 2.99B▲ 100.4% | 2.41B▼ 19.5% | 3.93B▲ 63.0% | 3.28B▼ 16.5% | -790.3M▼ 124.1% | 3.19B▲ 504.1% | 3.71B▲ 0% |
FCF Margin % | 23.53% | 38.55% | 35.89% | 48.24% | 31.8% | 43.95% | 33.22% | -7.17% | 26.45% | 30.28% |
FCF Growth % | 226.12% | 100.64% | 27.16% | 100.4% | -19.55% | 62.97% | -16.47% | -124.1% | 504.13% | 394.94% |
FCF per Share | 2.31 | 4.53 | 5.73 | 11.37 | 9.27 | 15.15 | 12.59 | -3.06 | 12.38 | 14.48 |
FCF Conversion (FCF/Net Income) | 3.21x | 0.61x | 1.33x | 1.20x | 1.13x | 1.24x | 0.98x | 0.92x | 0.92x | 0.86x |
Interest Paid | 68.7M | 66.46M | 55.6M | 54.5M | 56.3M | 52.3M | 43.1M | 30.5M | 0 | 12.9M |
Taxes Paid | 6.41M | 12.4M | 24.7M | 191.8M | 476.3M | 1.06B | 1.68B | 1.08B | 0 | 1.46B |
VRTX Key Ratios
Vertex Pharmaceuticals Incorporated (VRTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 15.59% | 64.74% | 22.37% | 36.71% | 24.93% | 27.67% | 22.99% | -3.15% | 22.54% | 23.93% |
Return on Invested Capital (ROIC) | 9.34% | 28.4% | 29.89% | 58.95% | 52.81% | 75.3% | 46.63% | -1.62% | 23% | 23.39% |
Gross Margin | 88.95% | 86.56% | 86.84% | 88.14% | 88.06% | 87.9% | 87.21% | 86.11% | 85.03% | 86.28% |
Net Margin | 10.59% | 68.8% | 28.27% | 43.7% | 30.92% | 37.2% | 36.68% | -4.86% | 32.74% | 35.4% |
Debt / Equity | 0.30x | 0.13x | 0.11x | 0.11x | 0.10x | 0.06x | 0.05x | 0.11x | 0.21x | 0.10x |
Interest Coverage | 0.77x | 19.72x | 24.84x | 54.60x | 45.40x | 78.23x | 100.32x | 9.12x | 357.95x | 488.09x |
FCF Conversion | 3.21x | 0.61x | 1.33x | 1.20x | 1.13x | 1.24x | 0.98x | 0.92x | 0.92x | 0.86x |
Revenue Growth | 46.2% | 22.46% | 36.59% | 49.07% | 22.06% | 17.91% | 10.51% | 11.66% | 9.57% | 10.41% |
Related:VRTX Dividend History·VRTX Revenue History·VRTX Price History·VRTX P/E History·VRTX Financial Ratios·VRTX Institutional Holders
VRTX SEC Filings & Documents
Vertex Pharmaceuticals Incorporated (VRTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
VRTX Frequently Asked Questions
Vertex Pharmaceuticals Incorporated (VRTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Vertex Pharmaceuticals Incorporated (VRTX) reported $12.26B in revenue for fiscal year 2025. This represents a 92044% increase from $13.3M in 1996.
Vertex Pharmaceuticals Incorporated (VRTX) grew revenue by 9.6% over the past year. This is steady growth.
Yes, Vertex Pharmaceuticals Incorporated (VRTX) is profitable, generating $4.34B in net income for fiscal year 2025 (32.7% net margin).
Dividend & Returns
Vertex Pharmaceuticals Incorporated (VRTX) has a return on equity (ROE) of 22.5%. This is excellent, indicating efficient use of shareholder capital.
Vertex Pharmaceuticals Incorporated (VRTX) generated $3.71B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.